Fudan oncology experts propose a "low toxicity" regimen for radiotherapy and chemotherapy for HPV related oropharyngeal cancer in the Chinese population, with reduced toxicity but no reduced efficacy

Release time:Apr 15, 2024 21:18 PM

The toxic side effects of radiotherapy and chemotherapy are important challenges that affect the quality of life of patients with oropharyngeal cancer. Recently, Professor Lu Xueguan and Professor Xu Tingting's team from the Radiation Therapy Center of Fudan University Affiliated Cancer Hospital released a research result, which for the first time confirms that patients with human papillomavirus related oropharyngeal cancer in the Chinese population can benefit from a "low toxicity" regimen of radiotherapy and chemotherapy: using a low-intensity treatment plan can significantly reduce the adverse effects of treatment toxicity on their quality of life while achieving the same therapeutic effect, and thus better return to society. This achievement was published online in the top international journal of radiation oncology.

It is reported that oropharyngeal cancer includes tonsil cancer, tongue root cancer, soft palate cancer, pharyngeal posterior wall cancer, etc. Human papillomavirus infection is one of the main causes of oropharyngeal cancer. In recent years, the global incidence rate of HPV infection related oropharyngeal cancer is increasing year by year due to changes in the living habits of people such as sexual behavior, accounting for more than 60% of new cases in the United States.

In China, the incidence of HPV related oropharyngeal cancer was once considered much lower than that of European and American countries, so it did not receive sufficient attention. According to previous statistical data from Professor Lu Xueguan and Professor Xu Tingting's team at the Radiation Therapy Center of Fudan University Affiliated Cancer Hospital, the overall positive expression rate of HPV in oropharyngeal cancer is 57.6%, and there are significant differences in lesions in different sub locations, with tonsil cancer being the highest, reaching 68.8%.

Professor Lu Xueguan stated that based on past diagnosis and treatment experience in China, the first treatment for HPV positive oropharyngeal cancer is mainly surgical intervention, supplemented by radiotherapy and chemotherapy. In recent years, a large number of studies have shown that the prognosis of HPV related oropharyngeal cancer is significantly better than that of HPV unrelated oropharyngeal cancer. One of the important reasons is that this tumor has high sensitivity to radiotherapy and chemotherapy.

Previously, the radiation therapy center of the tumor hospital used a comprehensive radiotherapy and chemotherapy model to treat a large number of HPV positive cases of oropharyngeal cancer. Retrospective data showed that this group of patients had a higher response rate after receiving induction chemotherapy, were relatively sensitive to radiotherapy and chemotherapy, and most patients could achieve long-term survival. This suggests that a non-surgical treatment model mainly based on radiotherapy and chemotherapy is one of the ideal choices for this patient population.

Professor Lu Xueguan's team further observed that after treatment, patients had varying toxic reactions such as difficulty swallowing and oral mucositis, which had a certain impact on their recovery and quality of life. Therefore, whether it is possible to further reduce the therapeutic toxicity of patients while retaining the therapeutic effect has become a key focus of the team's efforts.

A total of 48 newly diagnosed HPV positive oropharyngeal cancer patients were enrolled in this Phase II prospective study. After receiving two courses of docetaxel combined with cisplatin induced chemotherapy, patient screening was conducted. Patients who achieved deep remission in the primary lesion and cervical metastatic lymph node regression were considered to have high chemotherapy sensitivity and good prognosis. Subsequently, low-dose simple intensity modulated radiation therapy was given, while synchronous chemotherapy was exempted; Those who have not achieved deep remission will continue to receive standard synchronous radiotherapy and chemotherapy, including standard dose radiotherapy, combined with two cycles of synchronous cisplatin chemotherapy. In the end, 26/48 patients met the criteria for reducing treatment intensity, while 22/48 patients still received routine treatment.

The data shows that the 2-year progression free survival rate and overall survival rate of the entire group of patients are 85.4% and 93.6%, respectively. Among them, the low-intensity treatment group has a 2-year progression free survival rate and an overall survival rate of 100%. In addition, the incidence of grade 3/4 oral mucositis, grade 1/2 leukopenia, chemotherapy related nausea and vomiting, fatigue, weight loss, hyponatremia, and liver and kidney toxicity were significantly reduced in the low-intensity treatment group. Experts say that the results of this study have confirmed for the first time that low-intensity treatment can achieve reduced toxicity without reduced effectiveness in patients with HPV related oropharyngeal cancer in China. It can significantly reduce the adverse effects of treatment toxicity on the quality of life of patients, allowing them to return to normal life more fully.

It is reported that the Radiotherapy Center of the Cancer Hospital is currently conducting an IChoice-02 study, which uses PD-1 monoclonal antibody immunotherapy combined with TP regimen chemotherapy as an induction regimen to guide subsequent intensity reduction treatment. Currently, more than 50 patients have been enrolled, and the preliminary results are encouraging. The study will also attempt to use plasma free HPV-DNA liquid biopsy and multi omics analysis to predict therapeutic effects, providing important basis for future attempts to propose genotyping of oropharyngeal cancer and benefiting more HPV related oropharyngeal cancer patients.

Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer

Immunotherapy has been proven to achieve significant therapeutic effects in various solid tumors. However, for pancreatic cancer, known as the "king of cancer", immunotherapy has been ineffective. On August 4, Professor Yu Xianjun, Dean of the Cancer Hospital Affiliated to Fudan University, and Shi Si, Associate Professor of Pancreatic Surgery released a research achievement, which first found the key role of cysteine rich protein 1 in shaping the immunosuppressive microenvironment of pancreatic cancer, filled the gap in the research field of immunosuppressive microenvironment of pancreatic cancer, and provided a theoretical basis for precise immunotherapy of pancreatic cancer patients. Ductal adenocarcinoma of the pancreas is the main type of pancreatic cancer, accounting for about 90% of all pancreatic cancer. Due to its high malignancy and poor treatment effectiveness, pancreatic ductal adenocarcinoma has always been one of the most malignant tumors. In recent years, the level of surgical techniques and comprehensive treatment has been achieved

A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare
A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare

A 14-year-old girl has been experiencing symptoms such as protruding pupils, incomplete eye closure, corneal injury, restricted eye movement, and overall fatigue for several years. The physical discomfort and facial abnormalities caused by eye diseases have made her increasingly reticent, and her temperament is vastly different from before. At the Ophthalmology Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the pupil has been diagnosed with a rare thyroid ophthalmopathy combined with myasthenia gravis, which requires prompt treatment. However, considering the young age of the pupil, conventional hormone and radiation therapy cannot be used. Therefore, Zhou Huifang, Deputy Director of Ophthalmology and thyroid ophthalmology expert, has developed a targeted drug combined with surgical treatment plan for it, and targeted drug treatment will be performed first. Three months ago, I was hospitalized for one week with mydriasis and received intravenous targeted drug treatment. Afterwards, I went home for observation and followed up on time

The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease
The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease

According to the Statistics of Chinese Dry Eye Expert Consensus, the incidence rate of dry eye in China is about 21%~30%, and it is estimated that there are at least 300 million patients nationwide. The Dry Eye Diagnosis and Treatment Studio of Shanghai Eye Disease Prevention and Treatment Center was officially launched today. In the future, the studio will continuously improve the dry eye diagnosis and treatment standards, and form standardized diagnosis and treatment concepts and service models. Suitable technologies will be promoted to the community, allowing residents to enjoy convenient dry eye diagnosis and treatment services at their doorstep. Executive Dean and Party Secretary Gao Wei stated that this is also one of the livelihood service measures recently launched by the hospital around high-quality development and meeting the needs of the people. It is reported that dry eye syndrome is a chronic ocular surface disease caused by multiple factors. The instability of the tear film or imbalance of the ocular surface microenvironment caused by abnormal quality, quantity, and dynamics of tears can be accompanied by ocular surface inflammatory reactions, tissue damage, and nerve abnormalities, resulting in various discomforts in the eyes

The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice
The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice

The International Dental Implant Consensus Report, jointly written by the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine and renowned universities in the field of dentistry such as Harvard University, University of Zurich, University of Gothenburg, Columbia University, and University of Frankfurt, has recently been jointly published in top journals in the field of dentistry, including Clinical Periodontology and Clinical Dental Implant Research. This consensus has for the first time established an internationally unified core set of indicators for evaluating the clinical effectiveness of dental implants, covering the five key areas of the field of dental implants. It is of milestone significance for carrying out standardized clinical diagnosis, treatment, and research on dental implants. The core evaluation indicators determined by this consensus will become an important benchmark for scholars in the field of dental implants worldwide to conduct high-quality research. The consensus is composed of 8 top international experts in the field of oral implantation

Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases
Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases

Recently, Catherine, a British girl born in the 1990s, received autologous peripheral blood hematopoietic stem cell transfusion at the Cancer Center of Shanghai Jiahui International Hospital, and was successfully discharged from the warehouse. She is now on her way back to China after being discharged from the hospital. She is also the first patient at Shanghai Jiahui International Hospital to complete relevant treatments. In 2019, Catherine was diagnosed with Hodgkin's lymphoma in the UK, and after treatment, the disease completely improved. During her work and life in China in 2021, she went to seek medical attention due to multiple enlarged lymph nodes. Pathological biopsy confirmed a recurrence of Hodgkin's lymphoma, and through combined targeted drug treatment, her condition was temporarily under control. Last year in the second half of the year, when the disease recurred, the girl began to use immunotherapy combined with targeted drugs for treatment. Expert evaluation suggests that for young patients with hematological tumors, the risk of recurrence is high and treatment difficulty is increasing in the future. Autologous hematopoietic stem cell therapy is recommended